

UROTHELKRZINOM

DURAVELO-2: A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

PROSTATAKRZINOM

ARASTEP: A randomized, double-blind, placebo-controlled Phase 3 study of Darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer (Sponsor: Bayer)

EVO-PAR: A randomised, double-blind, placebo-controlled, phase III study of AZD5305 in combination with physician's choice new hormonal agents in participants with metastatic castration-sensitive prostate cancer with and without HRRm (Sponsor: AstraZeneca)

ARASAFE: A randomised, phase 3 trial comparing 3-weekly Docetaxel 75 mg/m² versus 2-weekly Docetaxel 50 mg/m² in combination with darolutamide + ADT in patients with mHSPC

Closed for recruitment

XALUTE: A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

Prostatae cancer outcomes – compare & reduce variation in DKG-zertifizierten Prostatakrebszentren

NIERENZELLKRZINOM

STELLAR 002: A dose-escalation and expansion study of the safety and efficacy of XL092 in combination with immuno- oncology agents in subjects with unresectable advanced or metastatic solid tumors

Closed for recruitment

Stand: 23. Juni 2025